MTD Determination, Safety and Efficacy of the Decitabine-Genistein Drug Combination in Advanced Solid Tumors and Non-Small Cell Lung Cancer

Inclusion Criteria: * Written Informed Consent. * Males or females. * 18-75 years. * Histologically or cytologically confirmed non-estrogen dependent advanced solid malignancy who has failed standard therapies and/or for which no curative therapeutic option exists (phase I) or ; * Histologically or cytologically confirmed NSCLC of stage IIIb or IV (phase IIa) that has failed or is ineligible to standard therapies. * One or more tumor lesions measurable by RECIST criteria * Life expectancy of at least 3 months. * ECOG performance of 2 or less. Exclusion Criteria: * Prior decitabine or genistein therapy. * Received cytotoxic agent, hormonal therapy, radiation therapy, or other targeted cancer therapies or investigational agent within 4 weeks prior to study entry. * Patients with confirmed estrogen receptor-positive cancers, or patients with a primary breast or endometrial cancer for which phenotyping analysis has not been performed. * Presence of uncontrolled brain metastases or leptomeningeal disease. * Uncontrolled cardiovascular disorders, including symptomatic heart failure, unstable angina and cardiac arrhythmias. * Inadequate baseline organ function as shown by following laboratory values : * Hemoglobin \< 90 g/L * Absolute neutrophil count \< 1,500 /microliter * Platelet count \< 100,000 /microliter * Total bilirubin \> 1.5 ULN * AST and ALT \> 2.5 ULN * Creatinine clearance \< 60 ml/min * To be dependent of oxygen treatment. * Active infections requiring antibiotics. * Pregnancy or breastfeeding. All women of child-bearing potential must have a negative pregnancy test prior to first receiving protocol therapy. * Known allergic reactions to soy derivatives or deoxycytidine derivatives. * Active alcohol or drug abuse. * Any co-morbid condition that in the judgment of the investigator renders the subject at high risk of treatment complication or reduces the probability of assessing clinical effect. * Other malignancies diagnosed within the last 5 years with the exception of Basal Cell Carcinoma of the skin. * Gastrointestinal disorders or abnormalities that may interfere with the absorption of genistein. * Patients unable to comply with the study protocol and follow-up schedule for any psychological, familial, sociological or geographical reason.